Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBP in mild to moderate acute ischemic stroke
NCT02905565Phase 2Completed
- Sponsor
- CSPC Pharmaceutical Group
- Start
- Feb 2018
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ischemic stroke comparing Placebo with NBP 800 mg (2 arms). Primary endpoint: Incidence rate of treatment-emergent adverse events at 90 days. Started Feb 2018; status: completed.
02
Drugs
butylphthalide
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT02905565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02905565.